Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes.
暂无分享,去创建一个
[1] T D Koepsell,et al. A General Method of Compliance Assessment Using Centralized Pharmacy Records: Description and Validation , 1988, Medical care.
[2] Laurel,et al. Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission , 2002, Medical care.
[3] E H Wagner,et al. Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.
[4] J. Menzin,et al. Potential short-term economic benefits of improved glycemic control: a managed care perspective. , 2001, Diabetes care.
[5] F. Camacho,et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.
[6] J L Cavanaugh,et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. , 1995, The American journal of psychiatry.
[7] R. Crum,et al. Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. , 2000, Diabetes care.
[8] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[9] John D. Voss,et al. The association between diabetes metabolic control and drug adherence in an indigent population. , 2002, Diabetes care.
[10] M. Charlson. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: A response , 1993 .
[11] R. Bauer,et al. Correlates of Medication Compliance in Non-Insulin-Dependent Diabetes Mellitus , 1987, Southern medical journal.
[12] R. Rogers,et al. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. , 1998, Journal of forensic sciences.
[13] C. Rand,et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. , 1999, Medical care.
[14] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[15] G. Dailey,et al. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. , 2001, Clinical therapeutics.
[16] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[17] G. Peterson,et al. Determinants of patient compliance, control, presence of complications, and handicap in non-insulin-dependent diabetes. , 1984, Australian and New Zealand journal of medicine.
[18] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[19] P. Guillausseau,et al. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. , 2003, Diabetes & metabolism.
[20] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[21] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[22] J. Jollis,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.
[23] P. Diggle,et al. Analysis of Longitudinal Data , 2003 .
[24] J. K. Won,et al. Effect of value–added utilities on prescription refill compliance and Medicaid health care expenditures–a study of patients with non–insulin–dependent diabetes mellitus , 1993, Journal of clinical pharmacy and therapeutics.
[25] K. Farmer,et al. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. , 1999, Clinical therapeutics.
[26] C. Sherbourne,et al. The impact of patient adherence on health outcomes for patients with chronic disease in the medical outcomes study , 1994, Journal of Behavioral Medicine.
[27] F. Nuttall,et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. , 1997, Archives of internal medicine.
[28] V. G. Guillén,et al. [Validity of 6 indirect methods in the evaluation of compliance to drug treatment of non-insulin dependent diabetes mellitus]. , 1997 .
[29] COMPARATIVE RESEARCH Predicting Adherence to Prescription Medication Purchase Among HMO Enrollees With Diabetes , 2015 .
[30] Leonard H. Epstein,et al. Developmental aspects of health compliance behavior , 1993 .
[31] P. Donnan,et al. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[32] J. Jollis,et al. Further evidence concerning the use of a clinical comorbidity index with ICD-9-CM administrative data , 1993 .
[33] B. Svarstad,et al. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. , 2001, Psychiatric services.
[34] W. Herman,et al. The intensification of drug therapy for diabetes and its complications: evidence from 2 HMOs. , 2004, The American journal of managed care.